Dehydronorketamine

Dehydronorketamine

Dehydronorketamine

Chemical compound

Dehydronorketamine (DHNK), or 5,6-dehydronorketamine, is a minor metabolite of ketamine which is formed by dehydrogenation of its metabolite norketamine.[1][2] Though originally considered to be inactive,[1][2][3] DHNK has been found to act as a potent and selective negative allosteric modulator of the α7-nicotinic acetylcholine receptor (IC50 = 55 nM).[4][5] For this reason, similarly to hydroxynorketamine (HNK), it has been hypothesized that DHNK may have the capacity to produce rapid antidepressant effects.[6] However, unlike ketamine, norketamine, and HNK, DHNK has been found to be inactive in the forced swim test (FST) in mice at doses up to 50 mg/kg.[7] DHNK is inactive at the α3β4-nicotinic acetylcholine receptor (IC50 > 100 μM) and is only very weakly active at the NMDA receptor (Ki = 38.95 μM for (S)-(+)-DHNK).[4] It can be detected 7–10 days after a modest dose of ketamine, and because of this, is useful in drug detection assays.[8]

Quick Facts Clinical data, ATC code ...

See also

References

  1. [1]
    Booker PD, Chadderton N (14 May 2014). "Intravenous Agents". In Bissonnette B (ed.). Pediatric Anesthesia. PMPH-USA. pp. 366–. ISBN 978-1-60795-213-8.
  2. [2]
    Lapidus KA, Mathew SJ (9 May 2013). "Ketamine in treatment-resistant depression". In Mann JJ, McGrath PJ, Roose SP (eds.). Clinical Handbook for the Management of Mood Disorders. Cambridge University Press. pp. 345–357 (347). doi:10.1017/CBO9781139175869.027. ISBN 978-1-107-06744-8.
  3. [3]
    Bearn J, O'Brien M (2015). Taba P, Lees A, Sikk K (eds.). ""Addicted to Euphoria": The History, Clinical Presentation, and Management of Party Drug Misuse". International Review of Neurobiology. 120. Elsevier Science: 205–233 (225). doi:10.1016/bs.irn.2015.02.005. ISBN 978-0-12-803003-5. PMID 26070759.
  4. [4]
    Moaddel R, Abdrakhmanova G, Kozak J, Jozwiak K, Toll L, Jimenez L, et al. (January 2013). "Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors". European Journal of Pharmacology. 698 (1–3): 228–234. doi:10.1016/j.ejphar.2012.11.023. PMC 3534778. PMID 23183107.
  5. [5]
    Lester RA (11 November 2014). Nicotinic Receptors. Springer. pp. 445–. ISBN 978-1-4939-1167-7.
  6. [6]
    Paul RK, Singh NS, Khadeer M, Moaddel R, Sanghvi M, Green CE, et al. (July 2014). "(R,S)-Ketamine metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function". Anesthesiology. 121 (1): 149–159. doi:10.1097/ALN.0000000000000285. PMC 4061505. PMID 24936922.
  7. [7]
    Sałat K, Siwek A, Starowicz G, Librowski T, Nowak G, Drabik U, et al. (December 2015). "Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: Role of activity at NMDA receptor". Neuropharmacology. 99: 301–307. doi:10.1016/j.neuropharm.2015.07.037. PMID 26240948. S2CID 19880543.
  8. [8]
    Xu QA (1 April 2013). Ultra-High Performance Liquid Chromatography and Its Applications. John Wiley & Sons. pp. 1–. ISBN 978-1-118-53398-7.
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Dehydronorketamine, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.